NasdaqGS - Nasdaq Real Time Price USD
Upstream Bio, Inc. (UPB)
10.38
+1.15
+(12.46%)
As of 2:43:37 PM EDT. Market Open.
Insider Purchases Last 6 Months
| Shares | Transactions | |
|---|---|---|
| Purchases | 0 | 0 |
| Sales | -- | 0 |
| Net Shares Purchased (Sold) | 0 | 0 |
| Total Insider Shares Held | 10.62M | -- |
| % Net Shares Purchased (Sold) | -- | -- |
Net Institutional Purchases Prior Quarter to Latest Quarter
| Shares | |
|---|---|
| Net Shares Purchased (Sold) | -- |
| % Change in Institutional Shares Held | -- |
Insider Transactions Reported - Last Two Years
| Insider | Transaction | Type | Value | Date |
|---|---|---|---|---|
| CHIMOVITS EREZ Director and Beneficial Owner of more than 10% of a Class of Security | Purchase at price 23.00 per share. | Indirect | 18,975,000 | Oct 15, 2024 |
| CHIMOVITS EREZ Director and Beneficial Owner of more than 10% of a Class of Security | -- | Indirect | -- | Oct 15, 2024 |
| ORBIMED ADVISORS, L.L.C. Director and Beneficial Owner of more than 10% of a Class of Security | Purchase at price 23.00 per share. | Indirect | 18,975,000 | Oct 15, 2024 |
| ORBIMED ADVISORS, L.L.C. Director and Beneficial Owner of more than 10% of a Class of Security | -- | Indirect | -- | Oct 15, 2024 |
| WELLINGTON BIOMEDICAL INNOVATION MASTER INVESTORS CAYMAN II Beneficial Owner of more than 10% of a Class of Security | -- | Direct | -- | Oct 15, 2024 |
| AI UPSTREAM LLC Beneficial Owner of more than 10% of a Class of Security | Purchase at price 23.00 per share. | Indirect | 27,025,000 | Oct 15, 2024 |
| AI UPSTREAM LLC Beneficial Owner of more than 10% of a Class of Security | -- | Indirect | -- | Oct 15, 2024 |
Related Tickers
MBX MBX Biosciences, Inc.
12.83
+3.30%
ZBIO Zenas BioPharma, Inc.
10.01
+5.09%
AVBP ArriVent BioPharma, Inc.
22.12
+4.09%
BCAX Bicara Therapeutics Inc.
10.15
+9.73%
ALMS Alumis Inc.
3.3050
-5.57%
MLYS Mineralys Therapeutics, Inc.
15.41
-1.09%
SYRE Spyre Therapeutics, Inc.
15.32
+0.23%
ELVN Enliven Therapeutics, Inc.
19.28
+8.50%
TRML Tourmaline Bio, Inc.
17.49
+4.87%
RAPP Rapport Therapeutics, Inc.
9.26
+11.97%